REBECCA HEBARD: Open Payments
NPI 1821708520 · INVERNESS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,322 in 48 payments from 14 companies in 2025. Trend: 2023 $1,021 · 2024 $1,323 · 2025 $1,322
Food & beverage: $1,322
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $300 |
| PFIZER INC. | 7 | $263 |
| Boston Scientific Corporation | 6 | $195 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 3 | $114 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $86 |
| Esperion Therapeutics, Inc. | 4 | $77 |
| Merck Sharp & Dohme LLC | 3 | $73 |
| Amgen Inc. | 4 | $64 |
| Novartis Pharmaceuticals Corporation | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
Products named: VYNDAQEL, WATCHMAN FLX, FARXIGA, LOKELMA, LifeVest, JARDIANCE, NEXLETOL, VERQUVO.
Industry payments across FL — which companies pay providers there.
